Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart drug delivers chemo directly to pancreatic cancer cells

NCT ID NCT07707674

Not yet recruiting Disease control Sponsor: Evopoint Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-phase trial tests an experimental drug called XNW28012 in people with metastatic pancreatic cancer whose disease has worsened after at least one prior treatment. XNW28012 is an antibody-drug conjugate designed to seek out a protein called tissue factor on cancer cells and deliver a chemotherapy drug directly to them. The study aims to evaluate the drug's safety, tolerability, and how it moves through the body, while also looking for signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an antibody-drug conjugate called XNW28012 that targets tissue factor and delivers a chemotherapy drug
What this could lead to
If successful, this could point toward a new treatment option for metastatic pancreatic cancer, a disease with few effective therapies.
What could go wrong
This is an early, small Phase 1 trial focused on safety and dosing, so it is too soon to know if XNW28012 will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Oklahoma University Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SCRI at Mary Crowley

    Dallas, Texas, 75230, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START - Midwest

    Grand Rapids, Michigan, 49546, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START - New York Long Island

    Lake Success, New York, 10042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START - San Antonio

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.